ERBB2 and breast carcinoma: The emergence of the HER2-targeted antibody drug Herceptin/trastuzumab and the small dual molecule EGFR/HER2 kinase inhibitor Tykerb/lapatinib has remarkably improved the survival of patients with breast cancer; therefore, these drugs have been incorporated into the standard protocols for breast cancer treatment [3].